Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BY 4.0mSphere

Transformative advances in Guillain–Barré syndrome research

  • Christine M. Szymanski1,2
  • Ashley M. Rogers1,2
  • Leandre M. Glendenning1,2
  • Dee Warmath3
  • Jarrod J. Mousa4
  • Tiffany M. Daugherty4
  • Nadja Zeltner5,6,7
  • Jessica L. McAlpine5,6
  • David R. Tribble8
  • Glen A. Cook9,10
  • Geert-Jan Boons1,11,12
  • Nowshin Papri13
7 more authors
  • Shoma Hayat13
  • Israt Jahan13
  • Zhahirul Islam13
  • Rachel J. Richardson14,15
  • Charles E. Whitehead-Tillery14,15
  • Julia A. Bell14
  • Linda S. Mansfield14,15
15 affiliations
  1. 1Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
  2. 2Department of Microbiology, University of Georgia, Athens, Georgia, USA
  3. 3College of Family and Consumer Sciences, Biomedical and Translational Sciences Institute, University of Georgia, Athens, Georgia, USA
  4. 4Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, Florida, USA
  5. 5Center for Molecular Medicine, University of Georgia, Athens, Georgia, USA
  6. 6Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia, USA
  7. 7Department of Cellular Biology, University of Georgia, Athens, Georgia, USA
  8. 8Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
  9. 9Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
  10. 10Department of Neurology, Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
  11. 11Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands
  12. 12Department of Chemistry, University of Georgia, Athens, Georgia, USA
  13. 13Gut-Brain Axis Laboratory, Infectious Diseases Division, icddr, b, Dhaka, Bangladesh
  14. 14Comparative Enteric Diseases Laboratory, Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, Food Safety & Toxicology, East Lansing, Michigan, USA
  15. 15Microbiology, Genetics and Immunology, College of Natural Sciences, Michigan State University, Biomedical and Physical Sciences, East Lansing, Michigan, USA
Read full textDOICite

Abstract

The Guillain–Barré Syndrome Innovation Alliance held its inaugural meeting focused on creating treatment solutions for Guillain–Barré syndrome (GBS), an autoimmune disease increasingly recognized as a postinfectious neuropathy and the most common cause of paralysis since vaccines for polio. These collaborators, funded by the Department of War, Congressionally Directed Medical Research Programs, and the National Institute of Allergy and Infectious Diseases, span institutes/universities, including the University of Georgia, Michigan State University, Florida State University, the University of Utrecht, the International Centre for Diarrhoeal Disease Research, and the Uniformed Services University of the Health Sciences. Group efforts span biochemistry, epidemiology, immunology, medicine, microbiology, microbial ecology, glycobiology, neurology, neuroscience, pharmacology, and multiomics data science/computational biology. Our team is committed to the advancement of two core objectives: expanding understanding of biological mechanisms of GBS and developing more efficacious, targeted therapies. We are dedicated to finding alternative therapies for patients unresponsive to intravenous immunoglobulin and to creating affordable options to eliminate financial barriers to care.

Related

  1. Hyperacute Guillain-Barré Syndrome: A Pathophysiological Interpretation
    José Berciano
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textNeurologyJ-STAGE
  2. Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barré Syndrome of a Severe Refractory Case
    Daniel Matovu
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textNeurologyJ-STAGE
  3. Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
    Yueqi Wang, Siqi Wang, Huijuan Fan +6
    ImmunotherapyPeer-reviewedLicence not statedFull textNeurologyPMC
  4. Reply to the Letter “Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barré Syndrome of a Severe Refractory Case”
    Sachiko Saito, Susumu Kusunoki, Noritoshi Arai
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textNeurologyJ-STAGE
  5. Guillain-Barré Syndrome in Late Pregnancy Following Respiratory Syncytial Virus Infection: A Diagnostic Dilemma.
    Rhiana Pereira-Lindley, Mesharck Gariba, Darshan Lal
    Clinical case reportsPeer-reviewedCC BYFull textNeurologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{szymanski2026transformative,
  title = {{Transformative advances in Guillain–Barré syndrome research}},
  author = {Christine M. Szymanski and Ashley M. Rogers and Leandre M. Glendenning and Dee Warmath and Jarrod J. Mousa and Tiffany M. Daugherty and Nadja Zeltner and Jessica L. McAlpine and David R. Tribble and Glen A. Cook and Geert-Jan Boons and Nowshin Papri and Shoma Hayat and Israt Jahan and Zhahirul Islam and Rachel J. Richardson and Charles E. Whitehead-Tillery and Julia A. Bell and Linda S. Mansfield},
  journal = {mSphere},
  year = {2026},
  month = sep,
  doi = {10.1128/msphere.00436-26},
  url = {https://doi.org/10.1128/msphere.00436-26},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Transformative advances in Guillain–Barré syndrome research
AU  - Christine M. Szymanski
AU  - Ashley M. Rogers
AU  - Leandre M. Glendenning
AU  - Dee Warmath
AU  - Jarrod J. Mousa
AU  - Tiffany M. Daugherty
AU  - Nadja Zeltner
AU  - Jessica L. McAlpine
AU  - David R. Tribble
AU  - Glen A. Cook
AU  - Geert-Jan Boons
AU  - Nowshin Papri
AU  - Shoma Hayat
AU  - Israt Jahan
AU  - Zhahirul Islam
AU  - Rachel J. Richardson
AU  - Charles E. Whitehead-Tillery
AU  - Julia A. Bell
AU  - Linda S. Mansfield
PY  - 2026
DA  - 2026/09/24
JO  - mSphere
DO  - 10.1128/msphere.00436-26
UR  - https://doi.org/10.1128/msphere.00436-26
AB  - The Guillain–Barré Syndrome Innovation Alliance held its inaugural meeting focused on creating treatment solutions for Guillain–Barré syndrome (GBS), an autoimmune disease increasingly recognized as a postinfectious neuropathy and the most common cause of paralysis since vaccines for polio. These collaborators, funded by the Department of War, Congressionally Directed Medical Research Programs, and the National Institute of Allergy and Infectious Diseases, span institutes/universities, including the University of Georgia, Michigan State University, Florida State University, the University of Utrecht, the International Centre for Diarrhoeal Disease Research, and the Uniformed Services University of the Health Sciences. Group efforts span biochemistry, epidemiology, immunology, medicine, microbiology, microbial ecology, glycobiology, neurology, neuroscience, pharmacology, and multiomics data science/computational biology. Our team is committed to the advancement of two core objectives: expanding understanding of biological mechanisms of GBS and developing more efficacious, targeted therapies. We are dedicated to finding alternative therapies for patients unresponsive to intravenous immunoglobulin and to creating affordable options to eliminate financial barriers to care.
SN  - 2379-5042
ER  -